Skip to main content
. 2022 Nov 15;36(1):87–96. doi: 10.20524/aog.2023.0758

Figure 2.

Figure 2

Forest plot of the overall survival for prophylactic use of HIPEC in gastric cancer, presented by group based on the use of CT (risk ratio values below 1 favor HIPEC and above 1 favor control)

HIPEC, hyperthermic intraperitoneal chemotherapy; OS, overall survival; CT, chemotherapy; DL, DerSimonian-Laird; IV, inverse variance